Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript

Imogen MansfieldCantor Fitzgerald & Co., Research Division Good morning, everyone. I am Imogen Mansfield. I’m a Biotech Analyst at Cantor, and I am delighted to be joined today by 2 legends, the CEO of Eikon, Roger Perlmutter; and Dr. Tim Yap, who is a legendary clinical trialist and physician at MD Anderson. So welcome. Thank [...] The post Eikon Therapeutics, Inc. (EIKN) Discusses Advances in…